10-Q: Bioxytran Faces Going Concern Doubt Amid Cash Shortage

Bioxytran, a clinical-stage pharmaceutical company, reported a significant accumulated deficit and negative working capital, raising substantial doubt about its ability to continue operations without immediate capital infusion.

Summary

• Bioxytran, Inc. reported a net loss of $1,318,197 for the six months ended June 30, 2025, compared to a net loss of $1,222,169 for the same period in 2024.
• The company generated a net profit of $35,437 for the three months ended June 30, 2025, a significant improvement from a $661,647 net loss in the prior year quarter, primarily due to a favorable change in the fair value of derivative liability.
• Cash on hand as of June 30, 2025, was $3,144, down from $5,154 at December 31, 2024.
• Total liabilities increased to $2,782,771 at June 30, 2025, from $1,930,642 at December 31, 2024.
• The accumulated deficit grew to $20,239,366 as of June 30, 2025, from $18,921,169 at December 31, 2024.
• Net working capital was negative $2,779,627 at June 30, 2025, worsening from negative $1,925,488 at December 31, 2024.
• Research and development expenses significantly increased to $452,000 for the six months ended June 30, 2025, from $27,000 in the prior year period.
• General and administrative expenses decreased substantially to $287,220 for the six months ended June 30, 2025, from $1,361,551 in the prior year period, largely due to management's payroll forfeiture and reduced promotional activities.
• The derivative liability increased to $684,002 at June 30, 2025, from $186,652 at December 31, 2024, reflecting the impact of the convertible note's price adjustment feature.

Sentiment

Score: 2

Explanation: The company is in a highly precarious financial position, explicitly stating it cannot fund operations beyond the current month without new capital and raising substantial doubt about its ability to continue as a going concern. While R&D is active and a quarterly profit was reported, the profit is due to a non-operating item, and the overall financial health is severely distressed with significant dilution risk from existing and future financing needs.

Positives

• The company reported a net profit of $35,437 for the three months ended June 30, 2025, reversing a $661,647 loss from the same period in 2024, primarily driven by a favorable change in derivative liability valuation.
• Research and development expenses increased significantly, indicating progress in product development, including $452,000 spent on the Acelluar Oxygen Carrier (AOC) development in the first six months of 2025.
• Management forfeited $941,890 in payroll and affiliated expenses during the first six months of 2025, reducing general and administrative costs and accounts payable to affiliates.

Negatives

• The company's cash balance is critically low at $3,144 as of June 30, 2025, and is not sufficient to fund projected operating requirements through July 2025.
• Net working capital deteriorated further to a deficit of $2,779,627, indicating severe liquidity issues.
• The accumulated deficit increased to over $20 million, highlighting a history of significant losses.
• Total liabilities increased substantially, driven by a significant rise in accounts payable and the derivative liability.
• Cash used in operating activities increased to $248,010 for the six months ended June 30, 2025, compared to $179,832 in the prior year period, indicating higher cash burn from operations.
• The company explicitly states that its financial conditions raise substantial doubt about its ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is uncertain due to insufficient capital resources and an accumulated deficit.
• Failure to raise additional capital through private placements, debt financing, or short-term bank loans could lead to cessation of operations or scaling back of business plans.
• The outstanding convertible notes, with their price adjustment features, pose a significant risk of substantial dilution to shareholders if converted, especially if the stock price remains depressed.
• The company's stock price on OTC Markets is deflated, making it difficult to raise funds without heavy discounting and further shareholder dilution.
• Material weaknesses exist in the company's internal control over financial reporting, specifically due to a lack of segregation of duties and inadequate review processes, which could lead to material misstatements.
• The company is reliant on funding to complete development activities and clinical trials, with no assurance that such funding will be available on acceptable terms or be sufficient.

Future Outlook

The company anticipates needing to raise at least $3,700,000 to fund operations for the next 15 months. It plans to publish results from its India Phase 1b/2a ProLectin-M trial within 90 days of May 1, 2025, and expects to schedule a Phase 3 trial if results are positive. FDA-approved PROTECT trial for ProLectin-M and CDSCO IND trials for ProLectin-I and ProLectin-F are expected to start in the third quarter of 2025. The next step for BXT-25 involves a 14-day repeated dose toxicity study. The company intends to pursue additional capital through private placements and public offerings, including a $2 million Private Placement Offering under Regulation D in spring 2025.

Management Comments

• "We do not currently have sufficient capital resources to fund operations."
• "We believe that if we can raise $3,700,000, we will have sufficient working capital to develop our business over the next approximately fifteen (15) months."
• "At funding raised that is significantly less than $3,700,000, we can likely continue to develop our business over the same 15-month period, but funding at that level will delay the development of our technology and business."
• "The Company is aware that its current cash on hand will not be sufficient to fund its projected operating requirements through the month of July 2025."
• "The Company is actively working on finding financing alternatives in order to continue its regulatory approval activities and intends to issue a Private Placement Offering under Regulation D in the order of $2 million in the spring of 2025."
• "There can be no assurance that these funds will be available on terms acceptable to the Company, or will be sufficient to enable the Company to fully complete its development activities or sustain operations."
• "If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations."
• "There can be no assurance that such a plan will be successful."

Industry Context

As a clinical-stage pharmaceutical company, Bioxytran operates in a high-risk, high-reward industry characterized by extensive research and development cycles, significant capital requirements, and stringent regulatory hurdles. The focus on hypoxia, viral diseases (COVID-19), and lung fibrosis places it in competitive therapeutic areas. Success is heavily dependent on positive clinical trial outcomes and securing substantial funding, which is a common challenge for early-stage biotech firms.

Comparison to Industry Standards

• The company's cash position of $3,144 is significantly below industry benchmarks for clinical-stage biotech companies, which typically require millions to tens of millions of dollars to sustain operations and advance drug candidates through trials.
• The accumulated deficit of over $20 million and negative working capital of nearly $2.8 million are indicative of a company in a very early, pre-revenue stage, which is common, but the explicit 'going concern' warning suggests a more precarious financial state than many peers.
• The increase in R&D spending to $452,000 for six months, while positive for pipeline development, is still modest compared to the multi-million dollar R&D budgets of more established clinical-stage companies like Moderna or BioNTech during their early COVID-19 vaccine development phases, or even smaller biotechs with active Phase 2/3 trials.
• The reliance on affiliate loans and the need for a $3.7 million capital raise for 15 months of operations highlights a funding gap that is typical for small biotechs but also signals a high burn rate relative to current capital.
• The significant derivative liability ($684,002) tied to convertible notes with aggressive conversion terms (e.g., 120% price difference reduction) is a red flag, indicating potentially highly dilutive financing structures that are often seen in distressed or very early-stage companies struggling to attract conventional funding.

Corporate Governance

Legal Proceedings

• The company may become involved in certain legal proceedings and claims which arise in the normal course of business.

Related Party Transactions

• The company holds a License Agreement for a medical device with an affiliated company (officers hold a majority interest), incurring a yearly maintenance cost of $5,000.
• Loan agreements with three affiliates totaling $502,255 at an 8% interest rate, with $22,948 in accrued interest as of June 30, 2025.
• Management forfeited $941,890 in payroll and affiliated expenses during the first six months of 2025, with $214,780 accrued in the prior year and $727,110 reversed from current year expenses.
• Un-issued shares liability to affiliates amounted to $26,242 as of June 30, 2025, for board members' attendance in meetings.

Stakeholder Impact

• Shareholders face significant potential dilution from the conversion of existing convertible notes due to their discounted conversion features, as well as from any future equity capital raises.
• Employees, particularly officers, have forfeited substantial payroll, indicating financial strain on the company's ability to compensate its leadership.
• Creditors, including affiliates, are subject to extended payables and loans, reflecting the company's liquidity challenges and reliance on related-party financing.

Next Steps

• Publication of results from the India Phase 1b/2a ProLectin-M trial within 90 days of May 1, 2025.
• Scheduling of a Phase 3 clinical trial with the CDSCO for ProLectin-M, provided positive Phase 1b/2a results.
• Expected start of the FDA-approved PROTECT trial (ProLectin-M) in the third quarter of 2025.
• Expected start of CDSCO IND trials for ProLectin-I and ProLectin-F in the third quarter of 2025.
• Proceeding with a 14-day repeated dose toxicity study for BXT-25 using New Zealand Rabbits and Wistar Rats.
• Actively seeking additional capital through private placements and public offerings.
• Issuance of a Private Placement Offering under Regulation D of approximately $2 million in the spring of 2025.

Key Dates

Recommendation

The company is in a critical financial state, explicitly stating it has insufficient cash to fund operations beyond July 2025 and raising substantial doubt about its ability to continue as a going concern. While a quarterly profit was reported, it was driven by a non-cash derivative revaluation, not core operational improvement. The accumulated deficit is significant, working capital is deeply negative, and there's a high risk of severe shareholder dilution from existing convertible debt and necessary future capital raises. The material weaknesses in internal controls further compound the risk. Given the dire liquidity, ongoing losses, and high dilution potential, the stock presents an extremely high-risk investment with a strong likelihood of further value erosion.

Keywords

Pharmaceutical, Clinical Stage, Hypoxia, Viral Diseases, BXT-25, ProLectin-M, ProLectin-I, ProLectin-F, SEC Filing, 10-Q, Biotechnology, Drug Development, Going Concern, Convertible Debt, Dilution, Clinical Trials, R&D, OTC Markets